Global registry for emerging invasive fungal infections
Official title: FungiScope - A Global Emerging Fungal Infection Registry
Run by University of Cologne · NCT01731353 · Data updated 2026-11-12
This study is collecting information about invasive fungal infections to better understand how they spread, how they are diagnosed, and how well different treatments work for people affected by them.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | University of Cologne Academic / other |
| Locations | 1 site (Cologne, North Rhine-Westphalia) |
| Status | Recruiting |
| Started | March 2003 |
| Main results expected | December 2026 |
| Study ends | December 2026 |
| Registry record updated | December 5, 2023 |
| Trial ID | NCT01731353 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with confirmed invasive fungal infections supported by cultural, histopathological, antigen, or DNA evidence.
✕Probably not a fit
Patients with infections caused by Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci, or those with endemic fungal infections will not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This registry aims to enhance understanding of invasive fungal infections by collecting data on the epidemiology, diagnostic methods, and clinical outcomes associated with these diseases. It will identify the fungal species responsible for infections worldwide and document the clinical patterns and diagnostic procedures used. Additionally, the registry will evaluate therapeutic regimens and their effectiveness while facilitating the sharing of clinical isolates among contributors. Molecular biology tools will also be developed for better strain identification in confirmed cases.
Why it matters
Potential benefit: If successful, this registry could lead to improved diagnosis and treatment strategies for invasive fungal infections, ultimately enhancing patient outcomes.
How similar studies have gone: While there have been various studies on fungal infections, this registry approach is relatively novel in its global scope and focus on emerging infections.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Cultural, histopathological, antigen or DNA evidence of invasive fungal infection Exclusion Criteria: * Infection due to Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci * Endemic fungal infection such as coccidioidomycosis or histoplasmosis * Colonisation or other non-invasive infection
Where it's running
-
University Hospital Cologne
Cologne, North Rhine-Westphalia, Germany Recruiting
Study contacts
- Principal investigator: Oliver A. Cornely, Professor — University Hospital of Cologne
- Study coordinator: Oliver A Cornely, Prof.
- Email: oliver.cornely@uk-koeln.de
- Phone: +49 221 478
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tracking invasive fungal infections after allogeneic hematopoietic stem cell transplant
We will follow people who had an allogeneic stem cell transplant to see how often serious fungal infections occur and which clinical factors predict them.
-
Treating breakthrough invasive fungal infections in blood cancer patients with liposomal amphotericin B versus isavuconazole/posaconazole
This project will test whether liposomal amphotericin B or isavuconazole/posaconazole works better and is safer for adults with blood cancers who develop breakthrough invasive fungal infections after antifungal prophylaxis.
-
Evaluating the effectiveness of amphotericin B and azoles for invasive fungal infections
This study looks at how well amphotericin B and azole antifungals work and how safe they are for patients with invasive fungal infections based on their medical records.
-
Immune monitoring during invasive mold infections.
This project will test whether tracking T-cell immune checkpoints can identify adults with invasive mold infections who might benefit from adding immunotherapy to antifungal treatment.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children
This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.